Stock Surges Following Positive Clinical Update Shares of Design Therapeutics (NASDAQ:DSGN) climbed 27% on Monday after the ...

Shares of Design Therapeutics jumped after the company reported positive data from a study of its DT-216P2 drug for Friedreich ataxia, a neuromuscular disease. The stock rose 10% to $15.85 in ...

Supported by phase 3 trial data showing significant SARA score improvements, levacetylleucine is on track to potentially become the first approved therapy for A-T.

IntraBio Inc., a global biopharmaceutical company focused on developing and commercializing therapies for neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has ...

Ataxia is a degenerative disease affecting the nervous system, presenting poor coordination and movement, difficulties with speech, walking, fine motor skills, swallowing, and vision. It mainly ...

Add Yahoo as a preferred source to see more of our stories on Google. Difficulty balancing or an inability to do so can be caused by any number of factors. Head injuries, migraines, alcohol use, ear ...

Ataxia has no cure. There are no medications that can specifically treat and cure the symptoms of ataxias. However, medications may ease the symptoms by treating the underlying condition that causes ...

Ataxia is a lack of muscle coordination that may affect a person’s speech, eye movements, and ability to swallow, walk, and pick up objects. It can happen due to certain health conditions, genetics, ...

Difficulty balancing or an inability to do so can be caused by any number of factors. Head injuries, migraines, alcohol use, ear infections and medications can all affect your musculoskeletal system ...